ZS | Intomics Revenue and Competitors

Kongens Lyngby, Den

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ZS | Intomics's estimated annual revenue is currently $7.4M per year.(i)
  • ZS | Intomics's estimated revenue per employee is $155,000

Employee Data

  • ZS | Intomics has 48 Employees.(i)
  • ZS | Intomics grew their employee count by -19% last year.

ZS | Intomics's People

NameTitleEmail/Phone
1
Marketing Operations ManagerReveal Email/Phone
2
Recruiting Practice Lead - SciencesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$28.5M18437%N/AN/A
#2
$20.6M1334%N/AN/A
#3
$25.3M16327%N/AN/A
#4
$9.3M60-27%N/AN/A
#5
$88.8M57327%N/AN/A
#6
$12.7M82-2%N/AN/A
#7
$6.8M44-28%N/AN/A
#8
$7.4M48-19%N/AN/A
#9
$88.8M57327%N/AN/A
#10
$18.3M1188%N/AN/A
Add Company

What Is ZS | Intomics?

ZS | Intomics is a highly specialized biomedical data analytics company. We derive core biological insights from analysis and integration of biomedical big data. We increase the success rate of drug discovery and development projects for clients in the pharmaceutical industry. With our world-leading expertise, unique value-added data sets and sophisticated systems biology platform, we help our clients with: • Discovering new biomarkers • Assessing the specificity of biomarkers • Linking biomarkers to the underlying biology • Identifying drug targets and MOA • Delivering personalized medicine solutions • Repositioning of drugs • Creating biological knowledge maps for data-driven decision-making To each client and project we deliver scientifically solid and innovative data analysis solutions tailored and executed by our panel of world-leading experts. Simply said, Intomics help you discover more from your data - better & faster.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19M6436%N/A
#2
$26.1M790%N/A
#3
$14.6M8129%N/A
#4
$20M1110%N/A
#5
$24.3M1570%N/A